Scancell Share Discussion Threads

[2tyke] 09/12/2024 17:45

Think I'm the only winner ever here in SCLP actually fraggle !
Yes ..I'm yours....your conscience. To 'try' and keep you honest.
As you see....it's a big task 😂

[fragma] 09/12/2024 17:31

I know, I can't believe how someone who lost a few hundred quid ages ago can hold so much bitterness and anger?And he's obviously got plenty of time on his hands to stew over it.No worries, every board has one angry bitter poster, and he's ours !

[2tyke] 09/12/2024 17:19

Data been coming in for years Nigel, and it's been very good. Wrong premise.
All about intellectual honesty.....you either have it ...or...

[nigelpm] 09/12/2024 17:07

Solid c.70% over subscription - would expect to see a run up as data comes in - obviously the data needs to be good to keep the show on the road.

[2tyke] 09/12/2024 16:53

I don't troll anything fraggle....if I see a really good investment...I take it.
Pointing out that a stock has been and was likely to be a poor investment, in advance, which this has been, is not trolling.
It simply indicates how yourself and poor old inane the car park attendant have been wrong.
All about intellectual honesty....you either have it ....or...

[inanaco] 09/12/2024 16:32

He is Waiting for his benefits payments .

[fragma] 09/12/2024 16:18

I see the troll is putting in double time today !!

[2tyke] 09/12/2024 16:04

That's right....no money in 'cures' going forward.
I think you'll find that everything old tykey says about markets and 'asset prices' is indeed correct.

[marcusl2] 09/12/2024 15:58

Punter
SMALL CAP IDEA: Scancell is becoming a key player in cancer immunotherapy
By IAN LYALL AT PROACTIVE INVESTORS FOR THISISMONEY.CO.UK

Updated: 13:53, 9 December 2024

e-mail
View comments
e-mail
Top
+99Home
For ambitious junior life sciences companies, often the ultimate goal is securing partnerships with well-funded industry players to propel drug development toward commercial success.

For many smaller innovators, bringing a promising molecule from the lab through clinical trials and onto the market is a daunting challenge requiring significant time and financial resources.

For Scancell Holdings, a UK-based specialist in immuno-oncology, this challenge has been met with two notable partnerships worth a potential £940million ($1.2billion) — both with Danish biotech company Genmab.

Genmab
The most recent deal grants Genmab exclusive global rights to develop and commercialise a monoclonal antibody from Scancell's GlyMab platform.

Analysts estimate an upfront payment of around $5million, alongside milestone payments tied to development, regulatory, and commercial achievements. Scancell will also earn royalties on net sales of products resulting from the collaboration.

The licensed antibody is one of five in Scancell's portfolio targeting glycan structures associated with cancer. These partnerships underscore the potential of Scancell's GlyMab platform, though the company's ambitions extend well beyond these agreements.

Deals: Scancell Holdings , a UK-based specialist in immuno-oncology, has struck partnerships worth a potential £940million ($1.2billion) — with Danish biotech company Genmab +1
Deals: Scancell Holdings , a UK-based specialist in immuno-oncology, has struck partnerships worth a potential £940million ($1.2billion) — with Danish biotech company Genmab

SCIB1: Progress in advanced melanoma
Scancell has made significant strides in developing SCIB1, its lead asset targeting advanced melanoma, a form of skin cancer.

The SCOPE trial, testing SCIB1 in combination with checkpoint inhibitors ipilimumab and nivolumab, has yielded promising results in 25 patients.

At six months, 80 per cent of participants experienced no disease progression, with 20 per cent achieving complete remission. The overall disease control rate — including stable disease or tumour shrinkage — stood at 84 per cent, and 72 per cent of patients showed significant tumour reduction, improving over time.

These results compare favourably with outcomes from checkpoint inhibitors alone, which typically achieve 65 per cent progression-free survival and a 16 per cent complete remission rate. The data suggest SCIB1 enhances both the durability and effectiveness of treatment.

RELATED ARTICLES
Previous
1
Next

SMALL CAP IDEA: Frustration for Futura Medical as enthusiasm...

SMALL CAP IDEA: Deltic Energy gas discovery marred by...
Share this article
Share
HOW THIS IS MONEY CAN HELP
What you need to know each week: Listen to the This is Money podcast
Dr Heather Shaw, an oncologist at University College Hospital in London, praised SCIB1 for its potential to improve first-line therapies for advanced melanoma patients while maintaining a strong safety profile.

Scancell's chief scientist, Professor Lindy Durrant, highlighted progression-free survival as a key metric for future trials, stating: 'The SCOPE study continues to yield excellent results with a PFS of 80 per cent and five patients now achieving a complete response.'

Advantages of SCIB1
SCIB1 is the only off-the-shelf DNA cancer vaccine currently in development for melanoma. Unlike personalised cancer vaccines, which are tailored to individual patients, off-the-shelf vaccines are expected to be less expensive, easier to manufacture, and more readily available.

Analysts at Panmure Liberum have noted the potential advantages of this approach, predicting that it could make Scancell a leader in this emerging field. Ease of use is enhanced by a tie-up with PharmaJet, a specialist in needle-free injections.

Modi-1
In addition to SCIB1, Scancell is advancing Modi-1, another phase II asset targeting renal cell carcinoma (RCC) initially.


Data from the ModiFY study, which combines Modi-1 with checkpoint inhibitors for RCC, is anticipated in the first half of 2025.

New leadership
Last month, Scancell appointed Dr Phil L'Huillier as chief executive, succeeding Professor Durrant.

L'Huillier brings a wealth of experience, having previously led CatalYm, where he advanced products from phase I to phase IIb and raised over $200million.

He has also been involved in the development of multiple biotech companies, including Achilles Therapeutics and Blink Therapeutics.

Panmure Liberum welcomed his appointment, stating: 'We expect the appointment to add company development experience to the solid scientific foundations of Scancell and should enable the maturation of the company as it reaches the next stage.'

Last week, L'Huillier hit the ground running as he unveiled plans to raise up to £9.5million of new investment made up of a placing of new shares at 10.5p each that will bring in at least £8.5million and a retail offer of stock.

Together with the cash already in the bank (£9.1million at the last count), the company believes it will have sufficient resources to continue development efforts until late 2026.

What's it all worth?
Panmure Liberum rates Scancell shares as a 'buy,' with a price target of 23.3p — a 65 per cent premium to the current price. The firm believes positive clinical data could trigger a re-rating of the stock, particularly as awareness grows around the potential of cancer vaccines.

'The growing awareness of the potential in the cancer vaccine field is translating to a rise in the profile of Scancell,' Panmure noted.

With two major partnerships, a strong pipeline, and a new CEO poised to drive its next phase of growth, Scancell is positioning itself as a key player in the competitive and evolving field of cancer immunotherapy.

[inanaco] 09/12/2024 15:52

science eradicated measles .. it was weasels like you that brought it back, trying to get into peoples heads with all your nonsense

[2tyke] 09/12/2024 15:34

However noble and beneficial to man-kind it would be..

[2tyke] 09/12/2024 15:33

Two comments inane....
Firstly...the stock market is only about profit or loss. Never science. That's where you go wrong fella !
Secondly....do you think a pharma would make a fortune out of a 'CURE' ?

[sci102] 09/12/2024 15:20

It was oversubscribed by 80%, so almost double. Not bad at all, but given that the allocated was 1M, it's not like people wanted to buy 20M.

Edit: about 70% actually.

[inanaco] 09/12/2024 15:02

just have to wait for the Bitcoin RNS .. Roger as a comparison

I wonder if it will cure cancer ?

[rogerbridge] 09/12/2024 14:41

I hope that we do not undersell on any future deals with Genmab.
It looks as though we hold some exceptionally lucrative IP.

[2tyke] 09/12/2024 14:20

Yes fraggle....they are queuing up for a box of confetti. Is inane getting married ? Surely not !
...........................
No as a rule of thumb for successful market investing.....NEVER follow the 'herd'.
Learn to be a single-minded independent investor. A CONTRARIAN.
That's where the profits lie.

[fragma] 09/12/2024 14:16

anyone who participated will only get 59% of what they applied for as it was 'significantly over subscribed'

[2tyke] 09/12/2024 14:05

Next news inane ?.....oh no....we all know what effect 'news' has here !!

[willoicc] 09/12/2024 14:04

9 December 2024

Scancell Holdings plc

("Scancell" or the "Company")

Result of Significantly Oversubscribed Retail Offer and Total Voting Rights

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to confirm, further to the announcements made on 4 December 2024, the result of its significantly oversubscribed Retail Offer and Capital Raise at the Issue Price of 10.5 pence per share. The Company announces that it has, conditional on Admission, raised aggregate gross proceeds of approximately £1 million pursuant to the Retail Offer. This is in addition to the previously announced oversubscribed Placing and Subscription which had significant participation from both existing and new healthcare specialist investors. Accordingly, the Company will issue a total of 9,523,809 new Ordinary Shares at the Issue Price pursuant to the Retail Offer.



In total, the Placing, Subscription and the Retail Offer have raised gross proceeds of approximately £11.3 million in aggregate for the Company.



Admission and Total Voting Rights

Application has been made for the Placing Shares, the Subscription Shares and the Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective on or around 10 December 2024.



Upon Admission, the Company's issued ordinary share capital will consist of 1,036,781,403 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 1,036,781,403. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.



The new Ordinary Shares to be issued pursuant to the Retail Offer will be issued free of all liens, charges and encumbrances and will, on Admission, rank pari passu in all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription and the Company's existing Ordinary Shares.



For the purposes of UK MAR, the person responsible for arranging for the release of this announcement on behalf of the Company is Sath Nirmalanathan, Chief Financial Officer.



Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 5:59 pm on 4 December 2024.

[markingtime] 09/12/2024 13:57

Sure. I know all that. I was just wondering if any applicants for stock yet know their allocations.The funds involved will certainly be known by the bookrunner, if not the public....depending on stake size.

[chilltime] 09/12/2024 13:19

It won’t be difficult to work out MT, public info eventually.

EG last time a fund out West and another more to the East via a subsidiary came in.
Listed in comments as new healthcare funds back then. Names known by a few for each.

Who involved this time will be known by some beyond the typical walls.

Nothing underhand there it’s just about knowing how to legitimately learn about it.

[inanaco] 09/12/2024 13:02

next news is a Glymab going into the clinic


and 19 patients using Modi1 doublet

[markingtime] 09/12/2024 12:44

Does anyone know the extent of the oversubscription or the basis of the allocations?

[octopus100] 09/12/2024 12:32

Good to see the funding away - but no surprise with such great skin cancer results and second Genmab deal vicariously confirm success of the product under the first.

Looks like they are well funded now. Next news per the company is ISCIB - expected Q1/Q2 2025

[marcusl2] 09/12/2024 11:17

Hopefully we see the share price recovering now.

23p M
30p Inan
27p Phoenixs
33p Gazza
32p miavoce
13p Loz
21p Connello
16p pharmaboy3
28p Flugelhorn
15p Nigel
29p Roger
34p Xylos
22p Plasybryn
18p MarkingTime
34p CW
10p dominoman (aka Private Frazer)
55p Moljen
30p keymosaby
45p Chilltime
48p Dom